Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 2nd Preview)
-
United Therapeutics to seek FDA: ralinepag halves risk of PAH clinical worsening
United Therapeutics reported a positive Phase 3 outcome for ralinepag and said it will pursue an FDA filing this year. The company linked the once-daily candidate to a substantial reduction in clinical worsening events in pulmonary arterial hypertension (PAH), positioning a potential launch in 2027. The Phase 3 results cited a 55% drop in risk of clinical worsening in the trial cohort, a hard clinical endpoint regulators prioritize in PAH approvals. United Therapeutics (corporate filings and company release) framed the result as a pivotal efficacy readout that supports a near-term regulatory submission. PAH is a progressive disease marked by high pulmonary artery pressure and right-heart strain; clinical-worsening endpoints typically bundle mortality, hospitalization and symptomatic decline. The company’s plan to file this year will shift investor focus to regulatory timelines and label expectations.
-
FDA lifts holds – Intellia clears path to resume Phase 3 CRISPR trials
The FDA lifted a clinical hold and allowed Intellia to resume one of two Phase 3 trials testing its CRISPR-based therapy nexiguran ziclumeran (nex-z) for transthyretin amyloidosis (ATTR). The agency imposed safety-driven entry criteria and monitoring requirements following a prior serious liver-toxicity event that resulted in a patient death. Intellia and its partner Regeneron aligned with FDA conditions that exclude patients with specified liver issues and severe cardiac instability, and require enhanced liver-enzyme surveillance and steroid guidance. CRISPR editing here is a one-time in vivo gene-editing approach to knock down transthyretin production; regulators are focusing on off-target and systemic toxicity signals. Analysts called the measures modest and flagged that the unknown mechanism behind the liver event remains an unresolved clinical and regulatory risk.
-
Aardvark halts Phase 3 after cardiac signals – shares tumble
Aardvark Therapeutics voluntarily paused dosing and enrollment in its Phase 3 HERO trial of ARD‑101 for Prader‑Willi syndrome after routine safety monitoring in a healthy‑volunteer study revealed reversible cardiac observations at supra-therapeutic doses. The company said it will comprehensively review the data to define next steps and optimal therapeutic dosing. The pause prompted a sharp market reaction, with Aardvark’s shares losing roughly half their value as investors repriced program and timeline risk. ARD‑101 is a gut‑restricted TAS2R pan‑agonist aimed at stimulating enteroendocrine satiety hormones; investigators and the company noted the cardiac signals were observed at doses above the intended therapeutic range, but the event forced enrollment suspension and delayed prospective readouts.
-
Roche nails another Phase 3 in MS – liver signal and deaths prompt scrutiny
Roche reported a third Phase 3 success for its BTK inhibitor fenebrutinib in multiple sclerosis, advancing plans for regulatory filings. The trial hit its primary efficacy endpoint, but investigators observed liver-related adverse events and a numerical imbalance in deaths in the fenebrutinib arm versus control, prompting internal analyses and safety follow‑up. Roche (company release and trial data) is advancing the program while conducting deeper safety assessments; regulators and clinicians will scrutinize hepatic safety as BTK inhibitors expand into neurology. Fenebrutinib’s efficacy readouts strengthen Roche’s late‑stage neurology portfolio, but the mortality and liver findings will shape label language, monitoring recommendations and market adoption.
-
FDA prefers randomized trial: UniQure’s AMT‑130 pathway stalls, stock plunges
The FDA told uniQure it does not view the existing single‑arm data package for AMT‑130, a gene therapy candidate for Huntington’s disease, as sufficient for approval and strongly recommended a prospective, randomized, double‑blind, sham‑surgery‑controlled study. UniQure confirmed the agency’s preference after a regulatory meeting and said plans to seek approval remain blocked. The guidance sent uniQure shares sharply lower as investors digested the need for a new randomized trial—an outcome that would substantially increase costs and extend timelines. AMT‑130 is an AAV‑based gene therapy intended to lower mutant huntingtin expression; regulators’ call for a randomized sham‑controlled design underscores FDA expectations for rigorous control arms in single‑procedure CNS gene‑therapy trials.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.